Oruka Therapeutics (ORKA) Set to Release Quarterly Earnings on Wednesday

Oruka Therapeutics (NASDAQ:ORKA) is anticipated to release its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Oruka Therapeutics to post earnings of ($0.5996) per share for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, analysts expect Oruka Therapeutics to post ($2.42) EPS for the current fiscal year and ($2.93) EPS for the next fiscal year.

Oruka Therapeutics Stock Performance

Shares of NASDAQ ORKA opened at $100.55 on Wednesday. The stock has a market cap of $6.66 billion, a PE ratio of -49.53 and a beta of -0.34. Oruka Therapeutics has a fifty-two week low of $25.23 and a fifty-two week high of $115.51. The stock has a fifty day moving average of $88.17 and a 200-day moving average of $69.56.

Insiders Place Their Bets

In other Oruka Therapeutics news, SVP Arjun Agarwal sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $106.66, for a total value of $1,066,600.00. Following the sale, the senior vice president owned 15,312 shares of the company’s stock, valued at $1,633,177.92. This trade represents a 39.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total value of $734,143.86. Following the completion of the sale, the insider directly owned 31,771 shares in the company, valued at approximately $2,935,004.98. The trade was a 20.01% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 179,950 shares of company stock worth $16,492,680 in the last ninety days. 23.49% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ORKA. BTIG Research reissued a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a report on Monday, October 19th. Mizuho set a $120.00 target price on Oruka Therapeutics in a research note on Thursday, September 3rd. Guggenheim reaffirmed a “buy” rating and set a $200.00 target price on shares of Oruka Therapeutics in a report on Monday, October 26th. HC Wainwright reaffirmed a “buy” rating on shares of Oruka Therapeutics in a report on Tuesday, October 27th. Finally, Wedbush reiterated an “outperform” rating and set a $165.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $133.00.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.